


## Claims

1. A compound of the formula Y:



where;

5  $R_1$  is O, S;

$R_2$  is a nitrogen-containing heterocycle, wherein a nitrogen is located at the 2 position relative to the (thio)urea bond;

$R_3$  is H,  $C_1$ - $C_3$  alkyl,

10  $R_4$ - $R_7$  are independently selected from H,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl, halo $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkanoyl, halo $C_1$ - $C_6$  alkanoyl,  $C_1$ - $C_6$  alkoxy, halo $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  alkyloxy- $C_1$ - $C_6$  alkyl, halo $C_1$ - $C_6$  alkyloxy $C_1$ - $C_6$  alkyl, hydroxy $C_1$ - $C_6$  alkyl, amino $C_1$ - $C_6$  alkyl, carboxy $C_1$ - $C_6$  alkyl, cyano $C_1$ - $C_6$  alkyl, amino, carboxy, carbamoyl, cyano, halo, hydroxy, keto;

X is  $-(CR_8R_8')_n-D-(CR_8R_8')_m-$ ;

15 D is a bond,  $-NR_9-$ ,  $-O-$ ,  $-S-$ ,  $-S(=O)-$  or  $-S(=O)_2-$ ;

n and m are independently 0, 1 or 2, provided that they are not both 0 when D is a bond;

$R_8$  and  $R_8'$  are independently H,  $C_1$ - $C_3$  alkyl, halo $C_1$ - $C_3$ alkyl, hydroxy, or  $R_8$  and  $R_8'$  together with their adjacent C atom is  $-C(=O)-$

20  $R_9$  is independently H,  $C_1$ - $C_3$  alkyl;

E is  $-CH_2-$ ,  $-CHOH-$ ,  $-C(=O)-$ ,  $-NR_9-$ ,  $-O-$ ,  $-S-$ ,  $-S(=O)_2-$ ;

p and q are independently 0, 1 or 2, where  $p+q \leq 2$ ;


$R_{10}$  is an optionally substituted, saturated or unsaturated 5-7 membered carbocyclic ring or an optionally substituted, saturated or unsaturated 5-7 membered heterocyclic ring containing 1 to 3 hetero atoms selected from O, N and S;

$R_{11}$  is independently H,  $C_1$ - $C_3$  alkyl, halo $C_1$ - $C_3$ alkyl, hydroxy

with the proviso that  $-(CHR_{11})_p-E-(CHR_{11})_q-R_{10}$  is not unsubstituted phenoxy;

and pharmaceutically acceptable salts and prodrugs thereof.

2. A compound according to claim 1, wherein  $R_1$  is O.
3. A compound according to claim 1, wherein  $R_2$  is pyridyl, isoxazolyl, benzothiazolyl, pyrimidinyl, pyrazinyl or thiazolyl.
4. A compound according to claim 3, wherein  $R_2$  is pyrid-2-yl, substituted at the 5 position with the  $-(CHR_{11})_p-E-CHR_{11})_qR_{10}$  moiety.
5. A compound according to claim 1, wherein  $R_3$  is H.
6. A compound according to claim 1, wherein the cyclopropyl moiety has an enantiomeric excess of the conformation depicted in the partial formulae:



10 where X is as defined, Y is the bridge to the (substituted) phenyl ring depicted in formula I and Z is bond to the (thio)urea- $R_2-(CHR_{11})_p-E-(CHR_{11})_q-R_{10}$  moiety depicted in formula I.

7. A compound according to claim 1 wherein the compound of formula I comprises an enantiomeric excess of the isomer showing negative optical activity.
8. A compound according to claim 1, wherein D is  $-O-$
9. A compound according to claim 8, wherein n is 0 and m is 1.
10. A compound according to claim 1, wherein  $R_4$  is hydrogen, fluoro or hydroxy.
12. A compound according to claim 1, wherein  $R_5$  is hydrogen, fluoro,  $C_{1-3}$  alkylcarbonyl or  $C_{1-3}$ alkyloxy.

13. A compound according to claim 1, wherein  $R_6$  is hydrogen, halo,  $C_1$ - $C_3$ alkyloxy,  $C_1$ - $C_3$ alkylcarbonyl, cyano or ethynyl.

14. A compound according to claim 13 wherein  $R_6$  is hydrogen, methoxy or fluoro.

15. A compound according to claim 1 wherein  $R_7$  is hydrogen, halo,  $C_1$ - $C_3$ alkyloxy, or  $C_1$ - $C_3$ alkylcarbonyl.

16. A compound according to claim 15, wherein  $R_7$  is fluoro.

17. A compound according to claim 1, wherein  $R_5$  and  $R_6$  are H and  $R_4$  and  $R_7$  are fluoro.

18. A compound according to claim 17, wherein X is  $-OCH_2$ ,  $R_1$  is O,  $R_2$  is pyrid-2-yl and  $R_3$  is H.

19. A compound according to claim 1, wherein  $-(CHR_{11})_p-E-(CHR_{11})_q$  is  $-O-$  or  $-S-$ .

20. A compound according to claim 1, wherein  $-(CHR_{11})_p-E-(CHR_{11})_q$  is  $-CHOH-$ .

21. A compound according to claim 1, wherein  $-(CHR_{11})_p-E-(CHR_{11})_q$  is  $-O$ -methylene or  $-O$ -ethylene.

22. A compound according to claim 21 wherein  $R_{10}$  is N-morpholino.

23. A compound according to claim 1, wherein  $R_{10}$  is optionally substituted cycloalkyl, cycloalkenyl, phenyl, pyridyl, isoxazolyl, furyl, pyrimidyl, pyrazinyl, thiazolyl, imidazolyl, indolyl, triazolyl, piperidiny, piperazinyl, or morpholinyl.

24. A compound according to claim 23, wherein  $R_{10}$  is halophenyl or cyanophenyl.

25. A compound according to claim 24, wherein  $R_{10}$  is fluorophenyl or fluorocyanophenyl.

26. A compound according to claim 23, wherein  $R_{10}$  is pyrid-3-yl or pyrid-4-yl.

27. A compound according to claim 26, wherein  $R_{10}$  is cyano or fluoro substituted pyrid-3-yl or pyrid-4-yl.

28. A pharmaceutical composition comprising a compound as defined in any preceding claim and a pharmaceutically acceptable vehicle or diluent therefor.

29. A composition according to claim 28, further comprising 1 to 3 additional HIV antivirals.

30. Use of a compound as defined in any of claims 1-27 in the manufacture of a medicament for the prophylaxis or treatment of HIV-1 infections.

31. Use according to claim 30, wherein the HIV-1 infection is a drug escape mutant.

32. Use according to claim 31, wherein the drug escape mutant comprises the K103I mutation.